-
Mashup Score: 1Correlation between MRD at the end of induction and EFS in pediatric T-cell lymphoblastic lymphoma - 1 month(s) ago
Here, we summarize a subgroup analysis of the Children’s Oncology Group AALL1231 trial investigating the correlation between MRD at the end of induction and event-free survival in pediatric patients with T-cell lymphoblastic lymphoma published by Hayashi et al.1 in Blood.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6STARGLO trial of glofitamab: primary endpoint met in R/R DLBCL - 1 month(s) ago
Results obtained from the phase III STARGLO trial showed that glofitamab met its primary endpoint of overall response in patients with R/R DLBCL who received at least one prior line of therapy.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 9TARMAC trial: Time-limited ibrutinib plus CAR T-cell therapy for the treatment of R/R MCL - 2 month(s) ago
Here, we summarize the results of the phase II TARMAC trial, published by Minson et al.1 in Blood, of the combination of time-limited ibrutinib and CTL019 CAR T-cells in patients with R/R MCL.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 22Optimal management of patients with R/R PTCL - 6 month(s) ago
Here, we summarize the current standard of care and future landscape of novel treatments for the optimal management of relapsed/refractory peripheral T-cell lymphoma.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
Can measurable residual disease status at the end of induction predict event-free survival outcomes in pediatric T-cell lymphoblastic lymphoma? Read our latest article to learn more: https://t.co/tizObwEq6T #lymphoma #lymsm #MedEducation https://t.co/6Dbu7qvCgt